What NewLimit does

NewLimit is a preclinical-stage biotechnology company founded in 2022 and headquartered in South San Francisco, California, developing epigenetic reprogramming medicines to restore youthful function in old cells with the goal of extending human healthspan. The company is built around a single integrated technology platform called the Discovery Engine, which combines the Ambrosia AI system for in silico payload design, the RESTORE-seq high-throughput molecular screening system that pairs DNA-barcoded transcription factors with single-cell epigenetic profiling, lipid nanoparticle (LNP)-formulated mRNA delivery of transcription factors in vivo, and humanized liver mouse models for preclinical validation. Per company disclosures, the Discovery Engine has scaled to test over 1,000 times more reprogramming payloads than the rest of the field combined and follows a reported biological scaling law for discovery rate.

The platform supports three therapeutic programs: a lead Metabolism program targeting hepatocytes (liver) with an initial indication in alcohol-related and fatty liver disease, an Immunology program restoring youthful function in aged T cells, and a Vascular program focused on rejuvenating endothelial cells in the kidney. The lead preclinical candidate for the liver was achieved three years after founding (versus a five-year projection), and the company plans to submit a clinical trial application in 2027 with first-in-human Phase I trials planned for the same year. The company also plans to open its own clinical research clinic in 2027.

NewLimit is pre-revenue with no approved products. The current go-to-market is community-led, centered on a Substack blog with over 4,000 subscribers publishing bi-monthly progress updates, a corporate website, an active Twitter account, and extensive earned media in Forbes, Stat News, TechCrunch, Endpoints, and FierceBiotech. Future commercial motion is expected to combine direct sales to hospitals and health systems, pharmaceutical partnerships and licensing (signaled by Eli Lilly's equity investment and former Lilly CSO Matthew Breyer's presence on the Scientific Advisory Board), and potential platform licensing of the Discovery Engine and Ambrosia AI. As of the June 2026 Series C, the company had raised approximately $650 million+ across all rounds at a roughly $3.1 billion post-money valuation.

Name

NewLimit

Legal name

NewLimit, Inc.

Website

https://newlimit.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

NewLimit is a preclinical-stage biotechnology company developing AI-driven epigenetic reprogramming medicines to restore youthful function in old cells. Its Discovery Engine supports three therapeutic programs in liver, immune, and vascular disease, with first human trials planned for 2027.

Ownership category

akta.pro rank

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Not yet generating revenue (preclinical): NewLimit is a preclinical-stage biotechnology company with no approved products and no current revenue. The company plans to initiate its first human clinical trial in 2027. Future revenue streams are expected to include direct sales of approved reprogramming medicines to hospitals and health systems, milestone payments and royalties from pharmaceutical collaborations (already signaled by the Eli Lilly investment), and potential platform licensing of the Discovery Engine and Ambrosia AI system.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

NewLimit is developing epigenetic reprogramming medicines that restore youthful function to old cells using transcription factor payloads delivered via lipid nanoparticle (LNP)-formulated mRNA. The company's lead program targets hepatocytes to treat alcohol-related and fatty liver disease, with parallel programs in T cell rejuvenation (immunology) and endothelial cell rejuvenation (vascular, initially kidney). All discovery is powered by an integrated Discovery Engine combining the proprietary Ambrosia AI system, RESTORE-seq high-throughput functional genomics screening, and single-cell epigenetic profiling.

Product overview

NewLimit operates a single unified R&D platform — the Discovery Engine — that combines proprietary AI (Ambrosia) with high-throughput molecular screening (RESTORE-seq) to discover epigenetic reprogramming medicines. The platform feeds three distinct therapeutic programs: (1) the lead Metabolism program targeting hepatocytes to treat liver disease and preserve metabolic health, (2) the Immunology program restoring youthful function in T cells for inflammatory/autoimmune conditions, and (3) the Vascular program rejuvenating endothelial cells (initially in the kidney) for kidney and cardiovascular disease. The Metabolism program is the most advanced, with a lead preclinical candidate advancing to manufacturing and planned first-in-human clinical trials in 2027. The Vascular and Immunology programs represent parallel expansion of the same reprogramming platform to additional cell types and disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Metabolism Program (Liver/Hepatocyte Reprogramming) NewLimit's lead therapeutic program developing reprogramming medicines to restore youthful function in old hepatocytes (liver cells), initially targeting alcohol-related liver disease and fatty liver disease, with the broader goal of preserving metabolic health. Aimed at patients with liver disease and clinicians (hepatologists) treating age-related metabolic decline.
• Immunology Program (T Cell Reprogramming) Therapeutic program working to restore specificity and a normal immunological state in old T cells, initially focused on inflammatory diseases of aging, with potential applications across inflammatory, infectious, and neoplastic diseases including rheumatoid arthritis. Aimed at patients with age-related immune dysfunction and immunology specialists.
• Vascular Program (Endothelial Cell Reprogramming) Therapeutic program developing reprogramming medicines to rescue endothelial cell function, initially focused on rejuvenating endothelial cells in the kidney to reverse the course of kidney disease and preserve renal function, with future applications in cardiovascular, metabolic, and cognitive health via vascular rejuvenation. Aimed at patients with kidney and vascular disease.

Quantifiable outcome

• 8X improvement in hepatocyte specificity over starting TF sequence
• +9 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Altos Labs: Direct competitor pursuing cellular rejuvenation programming to restore cell health and reverse disease, with a $3B raise in 2022 making it the most capitalized pure-play reprogramming company. Operates in the same epigenetic reprogramming space targeting biological rejuvenation.
• Retro Biosciences: Sam Altman-backed longevity biotech that raised $1B+ to develop cellular reprogramming, autophagy, and plasma-inspired therapies. Directly comparable to NewLimit on partial reprogramming modality and longevity disease focus.
• Calico Life Sciences: Alphabet/Google-backed longevity company focused on cellular reprogramming and aging biology. Jacob Kimmel (NewLimit CEO) previously led a reprogramming lab at Calico, making this a direct technical peer with effectively unlimited capital.
• Life Biosciences: Pure-play longevity biotech developing gene therapy and cellular reprogramming approaches to treat age-related diseases. Directly comparable focus on partial reprogramming and age-driven disease indications.
• Turn Biotechnologies: Epigenetic reprogramming company developing mRNA-based therapies to temporarily express Yamanaka factors and restore youthful cell function. Direct competitor in the same modality targeting age-related disease indications.
• AgeX Therapeutics: Biotechnology company developing therapeutics focused on biological aging and senescence, with stem cell and cellular regeneration programs. Comparable longevity/biogerontology focus with overlapping epigenetic and cell-rejuvenation themes.
• Unity Biotechnology: Clinical-stage longevity biotech developing senolytic medicines that selectively eliminate senescent cells to treat age-related diseases. Overlapping target disease areas (liver, ophthalmology) and longevity therapeutic modality, though different mechanism.

Emerging players

• Insilico Medicine: AI-driven drug discovery company combining generative AI with target identification for aging and age-related diseases, including fibrosis. Shares NewLimit's AI-driven platform approach but focuses more broadly on traditional small-molecule discovery.
• Rejuvenate Bio: George Church-cofounded biotech using gene therapy to reverse aging and treat age-related diseases in dogs and humans. Comparable focus on age-related disease reversal but via gene therapy rather than epigenetic reprogramming.

Regional players

• 4D Molecular Therapeutics: Clinical-stage gene therapy company where NewLimit's Head of Translation Melissa Calton previously served as VP of Early-Stage Product Development. Comparable preclinical-to-clinical translation of novel genetic medicines, though focused on AAV gene therapy rather than reprogramming.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/newlimit
• LinkedInlinkedin.com/company/newlimit

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NewLimit